Unique ID issued by UMIN | UMIN000041658 |
---|---|
Receipt number | R000045656 |
Scientific Title | Nationwide survey of 10mg/kg biweekly bevacizumab in combination with chemotherapy for the treatment of platinum-resistant ovarian cancer in Japan |
Date of disclosure of the study information | 2020/09/04 |
Last modified on | 2021/11/04 17:22:33 |
Nationwide survey of 10mg/kg biweekly bevacizumab in combination with chemotherapy for the treatment of platinum-resistant ovarian cancer in Japan
Nationwide survey of 10mg/kg biweekly bevacizumab in combination with chemotherapy for the treatment of platinum-resistant ovarian cancer in Japan
Nationwide survey of 10mg/kg biweekly bevacizumab in combination with chemotherapy for the treatment of platinum-resistant ovarian cancer in Japan
Nationwide survey of 10mg/kg biweekly bevacizumab in combination with chemotherapy for the treatment of platinum-resistant ovarian cancer in Japan
Japan |
Platinum-resistant ovarian cancer
Obstetrics and Gynecology |
Malignancy
NO
To evaluate the real-world usage, efficacy and safety of 10 mg/kg biweekly bevacizumab for the treatment of platinum-resistant ovarian cancer in Japan
Safety
To evaluate the real-world usage, efficacy and safety of 10 mg/kg biweekly bevacizumab for the treatment of platinum-resistant ovarian cancer in Japan
Others,meta-analysis etc
Not applicable |
Not applicable |
Female
Patients who received bevacizumab in combination with chemotherapy for the treatment of platinum-resistant ovarian cancer between November 2013 and December 2018
None
1st name | Takayuki |
Middle name | |
Last name | Enomoto |
Niigata University Graduate School of Medical And Dental Sciences
Department of obstetrics and gynecology
951-8510
1-757 Asahimachi-Dori, Chuo-ku Niigata city, Niigata 951-8510, Japan
025-227-2320
enomoto@med.niigata-u.ac.jp
1st name | Masayuki |
Middle name | |
Last name | Sekine |
Niigata University Graduate School of Medical And Dental Sciences
Department of obstetrics and gynecology
951-8510
1-757 Asahimachi-dori, Chuo-ku Niigata city, Niigata 951-8510, Japan
025-227-2320
masa@med.niigata-u.ac.jp
Japan Society of Gynecologic Oncology
Chugai Pharmaceutical Co., Ltd.
Profit organization
Institutional Review Board Niigata University Medical & Dental Hospital
754 Asahimachi-dori 1-bancho,Chuo-ku,Niigata-shi,Niigata,Japan
025-227-2436/2412
joho@med.niigata-u.ac.jp
NO
2020 | Year | 09 | Month | 04 | Day |
Not posted
Unpublished
https://jsgo.or.jp/62/common/saitakukekka_0511.pdf, https://pubmed.ncbi.nlm.nih.gov/34308512/
1633
This survey revealed the real-world usage of 10 mg/kg biweekly bevacizumab for the treatment of platinum-resistant ovarian cancer in Japan.
2020 | Year | 09 | Month | 02 | Day |
Refer to the published content
Refer to the published content
Refer to the published content
Refer to the published content
Completed
2018 | Year | 08 | Month | 31 | Day |
2018 | Year | 08 | Month | 31 | Day |
2018 | Year | 10 | Month | 10 | Day |
2018 | Year | 12 | Month | 31 | Day |
Usage survey
2020 | Year | 09 | Month | 02 | Day |
2021 | Year | 11 | Month | 04 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045656
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |